IRBESARTAN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H28N6O
Molecular Weight	428.5294
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5

InChI

InChIKey=YOSHYTLCDANDAN-UHFFFAOYSA-N

InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)

HIDE SMILES / InChI

Molecular Formula	C25H28N6O
Molecular Weight	428.5294
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf | https://www.drugs.com/cdi/irbesartan.html

Irbesartan is an angiotensin receptor blocker (ARB) used mainly for the treatment of hypertension. It was developed by Sanofi Research (now part of Sanofi-Aventis). It is marketed under the trade names Aprovel, Karvea, and Avapro. AVAPRO is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor and no agonist activity.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Type-1 angiotensin II receptor 40 Target ID: CHEMBL227 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/10193788 \| https://www.ncbi.nlm.nih.gov/pubmed/8230127	Antagonist 2778		1.1 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 567 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020757s055lbl.pdf	Primary		Approved 8429	AVAPRO Approved Use AVAPRO is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria Launch Date 1997
Diabetic nephropathy 35 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf	Primary		Approved 8429	AVAPRO Approved Use AVAPRO is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria Launch Date 1997

C_max

Value	Dose	Analyte	Population
3.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.6 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	900 mg 1 times / day multiple, oral dose: 900 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.04 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
19.8 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
20 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
31.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
32.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
34.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	900 mg 1 times / day multiple, oral dose: 900 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
44.8 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
9.3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
9.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
11 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
14 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
15 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
14 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
14 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	900 mg 1 times / day multiple, oral dose: 900 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
17 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
11 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
16 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
10% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020758s079lbl.pdf	unknown, unknown		IRBESARTAN serum	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
900 mg 1 times / day multiple, oral Highest studied dose Dose: 900 mg, 1 times / day Route: oral Route: multiple Dose: 900 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9549663 Page: p.247, p.250	healthy, 20-45 n = 9 Health Status: healthy Age Group: 20-45 Sex: M+F Population Size: 9 Sources: https://pubmed.ncbi.nlm.nih.gov/9549663 Page: p.247, p.250	Sources: https://pubmed.ncbi.nlm.nih.gov/9549663 Page: p.247, p.250
300 mg 1 times / day multiple, oral (max) Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Hypertension\|diabetic nephropathy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf Page: p.1	Disc. AE: Disorder fetal... AEs leading to discontinuation/dose reduction: Disorder fetal Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf Page: p.1
300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf Page: p.6	unhealthy Health Status: unhealthy Condition: Diabetic nephropathy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf Page: p.6	Disc. AE: Hyperkalemia... AEs leading to discontinuation/dose reduction: Hyperkalemia (2.1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf Page: p.6

AEs

AE	Significance	Dose	Population
Disorder fetal	Disc. AE	300 mg 1 times / day multiple, oral (max) Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Hypertension\|diabetic nephropathy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf Page: p.1
Hyperkalemia	2.1% Disc. AE	300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf Page: p.6	unhealthy Health Status: unhealthy Condition: Diabetic nephropathy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf Page: p.6

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587	substrate 1037 inhibitor 1767	inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A1 110 CYP1A2 1524 CYP2A6 707 CYP2B6 810 CYP2E1 882 Kv4.3 16 P-gp 1461 BCRP 699 MRP2 383

Drug as perpetrator

Target	Modality	Activity
CYP3A4 1925	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/10877007/ Page: -	no [IC50 224 uM]
CYP1A2 1692	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/10877007/ Page: -	no [IC50 483 uM]
CYP2A6 739	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/10877007/ Page: -	no [IC50 >1000 uM]
CYP2D6 1891	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/10877007/ Page: -	no [IC50 >1000 uM]
CYP2E1 970	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/10877007/ Page: -	no [IC50 >1000 uM]
BCRP 773	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/20222053/ Page: -	no
CYP1A1 218	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020757s071lbl.pdf#page=13 Page: 13.0	no
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020757s071lbl.pdf#page=13 Page: 13.0	no
MRP2 475	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/20222053/ Page: -	no
P-gp 1650	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/20222053/ Page: -	weak
CYP2C9 1819	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/10877007/ Page: -	yes [IC50 172 uM]
Kv4.3 16	inhibitor 3277 Sources: https://jpet.aspetjournals.org/content/304/2/862 Page: -	yes [IC50 7.2 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020757s071lbl.pdf#page=12 Page: 12.0	yes
CYP2C9 1037	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020757s071lbl.pdf#page=12 Page: 12.0	yes		yes (co-administration study) Comment: in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020757s071lbl.pdf#page=12 Page: 12.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://jpet.aspetjournals.org/content/304/2/862 Page: -

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:5959	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5959
ChemicalBook	CB4454663	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4454663
MolPort	MolPort-003-666-550	https://www.molport.com/shop/molecule-link/MolPort-003-666-550
MolPort	MolPort-006-167-687	https://www.molport.com/shop/molecule-link/MolPort-006-167-687
Selleck Chemicals	Irbesartan(Avapro)	http://www.selleckchem.com/products/Irbesartan(Avapro).html
ZINC	ZINC000003872931	http://zinc15.docking.org/substances/ZINC000003872931
eMolecules	32278040	https://www.emolecules.com/cgi-bin/more?vid=32278040
eMolecules	901986	https://www.emolecules.com/cgi-bin/more?vid=901986

PubMed

Title	Date	PubMed
End-stage renal failure after irbesartan prescription in a diabetic patient with previously stable chronic renal insufficiency.	2000 Nov	11104169
The comparative pharmacology of angiotensin II receptor antagonists.	2001	11333013
Irbesartan achieves consistent and effective use over 1 year.	2001 Apr-May	11474701
Irbesartan prevents the progression of kidney disease or death in patients with type 2 diabetes and high blood pressure.	2001 Aug-Sep	11766617
p38 Map kinase regulates vascular smooth muscle cell collagen synthesis by angiotensin II in SHR but not in WKY.	2001 Feb	11230337
Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL.	2001 Jul	11461726
Insurmountable AT(1) receptor antagonism: the need for different antagonist binding states of the receptor.	2001 Jul	11460825
Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery.	2001 Jul	11444497
Regression of left ventricular hypertrophy in human hypertension with irbesartan.	2001 Jun	11403367
Apoptosis and changes in contractile protein pattern in the skeletal muscle in heart failure.	2001 Mar	11412142
Headache, hypertension, and irbesartan therapy.	2001 Mar 12	11231724
Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure.	2001 May 1	11331262
[Milestone studies provide evidence: sartans have a nephroprotective effect. Evidence is clear].	2001 May 31	11460392
Drug companies should not have the final say in the design of clinical trials.	2001 Nov	11684568
Treatment with irbesartan or atenolol improves endothelial function in essential hypertension.	2001 Oct	11593101
Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients.	2001 Oct	11593098
A clinical trial in type 2 diabetic nephropathy.	2001 Oct	11576953
Angiotensin II receptor blockers and nephropathy trials.	2001 Oct	11574450
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].	2001 Oct 1	11601118
Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(D)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans.	2001 Oct 9	11591618
Adenovirus-mediated overexpression and stimulation of the human angiotensin II type 2 receptor in porcine cardiac fibroblasts does not modulate proliferation, collagen I mRNA expression and ERK1/ERK2 activity, but inhibits protein tyrosine phosphatases.	2001 Sep	11692164
Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis.	2001 Sep	11592599
Differentiation in the angiotensin II receptor 1 blocker class on autonomic function.	2001 Sep	11580884
Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.	2001 Sep-Oct	11588406
Angiotensin peptides modulate bradykinin levels in the interstitium of the dog heart in vivo.	2002 Jan	11752132

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Hypertension Initial dose: 150 mg orally once a day Maximum dose: 300 mg orally once a day Usual Adult Dose for Diabetic Nephropathy Target maintenance dose: 300 mg orally once a day Use: Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (greater than 300 mg/day) in patients with type 2 diabetes and hypertension.

Route of Administration: Oral

In Vitro Use Guide

0.1 uM irbesartan completely blocked the maximum response to Ang I (from 45.8 +/- 6.7% to 1.9 +/- 1.9%, p < 0.001)

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:40:25 GMT 2023` Edited by `admin` on `Fri Dec 15 15:40:25 GMT 2023`
Record UNII	J0E2756Z7N
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IRBESARTAN

Official Name

English

1,3-DIAZASPIRO(4.4)NON-1-EN-4-ONE, 2-BUTYL-3-((2'-(1H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-4-YL)METHYL)-

Systematic Name

English

IBERSARTAN/HYDROCHLOROTHIAZIDE TEVA COMPONENT IBERSARTAN

Brand Name

English

AVALIDE COMPONENT IRBESARTAN

Common Name

English

IRBESARTAN [USP MONOGRAPH]

Common Name

English

IRBESARTAN COMPONENT OF KARVEZIDE

Brand Name

English

irbesartan [INN]

Common Name

English

IRBESARTAN [MI]

Common Name

English

IBERSARTAN/HYDROCHLOROTHIAZIDE ZENTIVA COMPONENT IBERSARTAN

Brand Name

English

IRBESARTAN ZENTIVA

Brand Name

English

IRBESARTAN [USP-RS]

Common Name

English

IBERSARTAN/HYDROCHLOROTHIAZIDE COMPONENT IBERSARTAN

Brand Name

English

IRBESARTAN [EP IMPURITY]

Common Name

English

SARBEVEL

Brand Name

English

IRBESARTAN [VANDF]

Common Name

English

IRBESARTAN TEVA

Brand Name

English

IRBESARTAN [EMA EPAR]

Common Name

English

IRBESARTAN [USAN]

Common Name

English

IRBESARTAN COMPONENT OF IFIRMACOMBI

Brand Name

English

COAPROVEL COMPONENT IRBESARTAN

Brand Name

English

IRBESARTAN BMS

Brand Name

English

BMS-186295

Code

English

Irbesartan [WHO-DD]

Common Name

English

IRBESARTAN [JAN]

Common Name

English

IRBESARTAN [EP MONOGRAPH]

Common Name

English

IRBESARTAN COMPONENT OF AVALIDE

Common Name

English

IBERSARTAN COMPONENT OF IBERSARTAN/HYDROCHLOROTHIAZIDE TEVA

Brand Name

English

IFIRMACOMBI COMPONENT IRBESARTAN

Brand Name

English

SR 47436

Code

English

IRBESARTAN COMPONENT OF COAPROVEL

Brand Name

English

SR-47436

Code

English

IRBESARTAN [USP IMPURITY]

Common Name

English

IRBESARTAN [ORANGE BOOK]

Common Name

English

AVAPRO

Brand Name

English

2-BUTYL-3-(P-(O-1H-TETRAZOL-5-YLPHENYL)BENZYL)-1,3-DIAZASPIRO(4.4)NON-1-EN-4-ONE

Common Name

English

NSC-758696

Code

English

IRBESARTAN [MART.]

Common Name

English

KARVEA

Brand Name

English

IBERSARTAN COMPONENT OF IBERSARTAN/HYDROCHLOROTHIAZIDE ZENTIVA

Brand Name

English

Classification Tree Code System Code

EMA ASSESSMENT REPORTS

IFIRMACOMBI (AUTHORIZED: HYPERTENSION)